Therefore, the goal of this study was to evaluate the effect of the BSA targeted-NLC-Pip and untargeted-NLC-Pip on the viability, proliferation, and levels of cell cycle damage and apoptosis in the colon (LoVo), breast (MCF7), and ovarian (SKOV-3) adenocarcinoma cell lines. This evidence concerns the gene PIP and adenocarcinoma.